Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus sorafenib or lenvatinib as first-line treatment for advanced hepatocellular carcinoma
2019-000252-34Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hepatocellular carcinoma (HCC) comparing Nivolumab + ipilimumab, Sorafenib and Lenvatinib (3 arms). Primary endpoint: Overall survival. Started Sep 2019; status: active.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-000252-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000252-34.